Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis
T-cell/histiocyte-rich B-cell lymphoma (THRLBCL) is an uncommon variant of diffuse large B-cell lymphoma (DLBCL). Historically, it is considered an aggressive variant with poorer outcomes; however, recent analyses suggest that outcomes may be better for patients treated in the rituximab era. We reviewed THRLBCL cases who were diagnosed in MSKCC from January 2000 to October 2019. A total of 67 patients were included with a median follow-up of 5.4 years (0.5-13.8). Frontline treatment included R-CHOP or R-CHOP-based treatment in 48%, R-EPOCH in 12%, R-CHOP/R-ICE in 33% and other palliative treatments in 7.5%. In the whole cohort, 5-year EFS and OS was 59% and 79%, respectively. In an analysis of patients who received therapy with R-CHOP-14 × 4 followed by ICE/R-ICE × 3 compared to patients who were treated with R-CHOP or R-CHOP based treatment, CR rates were 95% and 70%, respectively (<i>p = 0.023</i>). The R-CHOP/R-ICE regimen was also associated with higher event-free survival (5-year EFS of 80% vs 50%; <i>p = 0.006</i>) and overall survival (5-year OS of 100% vs 72%; <i>p = 0013</i>). Our study demonstrates better outcomes among patients with THRLBCL compared to historical data. Our findings suggest that treatment with a higher intensity regimen with noncross resistance, such as R-CHOP/R-ICE is reasonable approach for patients with newly diagnosed THRLBCL.
Authors
- Craig H. Moskowitz (ORCID: https://orcid.org/0000-0002-9189-3152)
- Efrat Luttwak (ORCID: https://orcid.org/0000-0003-0212-2135)
- Raphaël Steiner (ORCID: https://orcid.org/0000-0003-3717-3629)
- Paul A. Hamlin (ORCID: https://orcid.org/0000-0001-9500-1804)
- Ariela Noy (ORCID: https://orcid.org/0000-0002-3001-4898)
- Paola Ghione (ORCID: https://orcid.org/0000-0001-6986-7954)
- Jennifer Kimberly Lue (ORCID: https://orcid.org/0000-0001-8153-1820)
- Santosha A. Vardhana (ORCID: https://orcid.org/0000-0002-3100-1298)
- Andrew M. Intlekofer (ORCID: https://orcid.org/0000-0001-9046-6549)
- Esther N Drill (ORCID: https://orcid.org/0000-0002-3315-4538)
- Pallawi Torka (ORCID: https://orcid.org/0000-0002-1681-5883)
- Colette Owens
- Alexander P. Boardman (ORCID: https://orcid.org/0000-0001-7169-9275)
- Zachary D. Epstein‐Peterson (ORCID: https://orcid.org/0000-0002-5942-2502)
- Andrew David Zelenetz (ORCID: https://orcid.org/0000-0003-1403-6883)
- Alison J. Moskowitz (ORCID: https://orcid.org/0000-0002-3408-050X)
- William L. Johnson (ORCID: https://orcid.org/0000-0003-2616-2553)
- Steven M. Horwitz (ORCID: https://orcid.org/0000-0002-6399-2006)
- Philip C. Caron
- Gilles Salles (ORCID: https://orcid.org/0000-0002-9541-8666)
- Robert N. Stuver (ORCID: https://orcid.org/0000-0003-0991-5170)
- Anita Kumar (ORCID: https://orcid.org/0000-0002-1381-5810)
- Lorenzo Falchi (ORCID: https://orcid.org/0000-0003-1531-3838)
- Maria Lia Palomba
- E Robin
Institutions
- Mount Sinai Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Miami Health System (US)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1080/10428194.2025.2465553
- Citations
- 2
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94